Jane Henderson, Chief Financial Officer at Apogee Therapeutics, Inc. (APGE), sold 2,000 shares at $90.00 ($180K) on 2026-04-16, disclosed to the SEC on 2026-04-17.
Scheduled sale ($180k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| APGE | SELL | 2026-03-27 | $170K | — | Filing → |
| APGE | SELL | 2026-03-04 | $140K | — | Filing → |
| APGE | SELL | 2026-02-04 | $132K | — | Filing → |